Strontiumranelat in der Therapie der postmenopausalen Osteoporose bei erst- und vorbehandelten Patientinnen

Zusammenfassung

Ziel: Die prospektive, nichtinterventionelle OLYMP-Studie untersucht die Wirkung von Strontiumranelat (SR) bei postmenopausaler Osteoporose (PMO) hinsichtlich Schmerzen und Lebensqualität unter Praxisbedingungen.

Design: 3383 Patienten mit PMO wurden von 1131 niedergelassenen Ärzten in Deutschland mit SR 2 g einmal täglich oral über drei Monate therapiert. Lebensqualität (QoL), Schmerzen, Komedikation, Frakturen, Knochendichte, Verträglichkeit und Compliance wurden deskriptiv an 3164 Patienten (ITT) analysiert. 39,1 % der Patienten waren mit Bisphosphonaten (BP) vorbehandelt, 26 % der Patienten waren > 75 Jahre alt.

Ergebnisse: Nach drei Monaten SR verbesserten sich die Schmerzen um 32,3 % (Patienten mit BP-Vorbehandlung: 28,3 %, Patienten ohne Vorbehandlung: 35,6 %, Patienten > 75 Jahre: 28,6 %) und die QoL um 27,5 % (Patienten mit BP-Vorbehandlung: 24,5 %, Patienten ohne Vorbehandlung: 30,2 %, Patienten > 75 Jahre: 24,4 %). SR wurde bei 93 % der Patienten als sehr gut bzw. gut bewertet und bei 93,2 % der Patienten nach drei Monaten fortgesetzt. UAWs traten bei 2,4 % der Patienten auf.

Zusammenfassung: OLYMP bestätigt unter Praxisbedingungen die gute Wirksamkeit und Verträglichkeit von SR bei PMO unabhängig von Alter und BP-Vorbehandlung mit einer raschen Schmerzreduktion und Verbesserung der QoL.

Summary

Aim: The prospective non-interventional OLYMP-study analysed the therapeutic effects of strontium ranelate (SR) in the therapy of postmenopausal osteoporosis (PMO) with respect to pain and the quality of life under routine practice.

Design: 3383 patients with PMO were treated by 1131 physicians in Germany with SR, 2 g once daily orally for 3 months. Quality of life (QoL), pain, co-medication, fractures, BMD, tolerability and compliance were descriptively documented in 3164 patients (ITT). 39.1 % of the patients were pre-treated with bisphosphonates (BP), 26 % were > 75 years old.

Results: After 3 months with SR, pain was reduced by 32.3 % (with BP pre-treated patients: −28.3 %; patients without pre-treatment: −35.6 %; patients > 75 y.: −28.6 %). QoL improved by 27.5 % (in BP pre-treated patients: +24.5 %; patients without pre-treatment: +30.2 %; patients >75 y.: +24.4 %). 93 % of the patients reported SR as good or very good, 93.2 % continued SR therapy. Adverse events occurred in 2.4 % of the patients.

Conclusion: The OLYMP-study confirmed under daily practice conditions the good efficacy and tolerability of SR in PMO patients, independent of age or pre-treatment with BP, with an early improvement in the quality of life and a reduction in pain.

Schlüsselwörter

Postmenopausale Osteoporose - Strontiumranelat - OLYMP-Studie - Bisphosphonat-Vorbehandlung

Keywords

Postmenopausal osteoporosis - strontium ranelate - OLYMP - pre-treatment with bisphosphonates

• Literatur

• 1 Atkins GJ. et al. Strontium ranelate treatment of human primary osteoblasts promotes an osteocytelike phenotype while eliciting an osteoprotegerin response. Osteoporos Int 2009; 20 (04) 653-664.
• 2 Cauley JA, Thompson DE, Ensrud KC. et al. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11 (07) 556-561.
• 3 Cummings SR, Melton L. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.
• 4 Dachverband Osteologie e. V. (DVO). OsteoporoseLeitlinie. Prophylaxe, Diagnostik und Therapie – bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr. Stuttgart: Schattauer 2006.
• 5 DVO-Leitlinie. Osteoporose des älteren Menschen. 2003 www.dv-osteologie.org/uploads/archiv/arch iv2003/leitl_kf_alter.pdf.
• 6 Fachinformation. Protelos 2 g. 2009.
• 7 Gennari C. Analgesic effect of calcitonin in osteoporosis. Bone 2002; 30 (05) 67S-70S.
• 8 Häussler B, Gothe H, Göl D. et al. Epidemiology, treatment and costs of osteoporosis in Germany: the BoneEVA study. Osteoporos Int 2007; 18 (01) 77-84.
• 9 Kado DM, Browner WS, Palermo L. et al. Vertebral fractures and mortality in older women: the study of osteoporotic fractures. Arch Int Med 1999; 338: 355-358.
• 10 Kanis J, Burlet N, Cooper C. et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19: 399-428.
• 11 Linde L, Sörensen J, Ostergaard M. et al. Health-related quality of life: validity, reliability and responsiveness of SF-36, 15D, EQ-5D[corrected]RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol 2008; 35 (08) 1528-1537.
• 12 Marquis P, Cialdella P, De la Loge C. Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Quality of Life Research 2001; 10: 555-566.
• 13 Marquis P, De La Loge C, Diaz-Curiel M. et al. Beneficial effects of Strontium ranelate on the quality of life in patients with vertebral Osteoporosis. Osteoporos Int. 2005 16. 54 Abstract P223.
• 14 Marquis P, Roux C, Diaz-Curiel M. et al. Long-term beneficial effects of strontium ranelate on the quality of life in patients with vertebral osteoporosis (SOTI study). Osteoporos Int. 2007 18. (Suppl 1): 123, P296.
• 15 McCarthy M, Chang C, Pickard A. et al. Visual Analog Scales for Assessing Surgical Pain. J Am Coll Surg 2005; 201 (02) 245-252.
• 16 Meunier PJ, Reginster JY. Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis. Osteoporos Int 2003; 14 (Suppl. 03) S66-S76.
• 17 Meunier PJ, Roux C, Seeman E. et al. The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women With Postmenopausal Osteoporosis. New England Journal of Medicine 2004; 350 (05) 459-468.
• 18 Reginster JY, Felsenberg D, Boonen S. et al. Effects of long-term strontium ranelate treatment on the risk of non.vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthritis and Rheum 2008; 58 (06) 1687-1695.
• 19 Reginster JY, Sawicki A, Roces AVarela. et al. Strontium ranelate 8 years efficacy on vertebral and non vertebral fractures in postmenopausal osteoporotic women. Osteoporos Int. 2008 19. Suppl 1 P311, S131.
• 20 Reginster JY, Seeman E, De Vernejoul MC. et al. Strontium Ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS Study. J Clin Endocrinol Metab 2005; 90 (05) 2816-2822.
• 21 Ringe JD. Strontiumranelat bei postmenopausaler Osteoporose. Arzneimitteltherapie 2007; 25 (06) 216-221.
• 22 Ringe JD, Dorst A, Faber H, Farahmand P. Treatment of osteoporosis in men with Strontium ranelate: results of a prospective controlled trial in 152 patients. Osteoporos Int. 2008 19. Suppl. 1: 13, OC24.
• 23 Seeman E, Vellas B, Benhamou C. et al. Strontium ranelate reduces risk of vertebral and non-vertebral fractures in women aged eighty years and older. J Bone Miner Res 2006; 21 (07) 1113-1120.
• 24 Seeman E, Vellas B, Benhamou C. et al. Sustained 5-year vertebral and non-vertebral fracture risk reduction with Strontiumranelate in elderly women with Osteoporosis. Osteoporos Int. 2006 18. (02): Abstract OC 39.
• 25 Seeman E, Vellas B, Roux C. et al. First Demonstration Of The Efficacy of An Anti-Osteoporotic Treatment In Very Elderly Osteoporotic Women. JBMR 2004; 19 (01) S57.